Neoadjuvant chemotherapy plusintensity-modulated radiotherapy versusconcurrent chemoradiotherapy plusadjuvant chemotherapy forthe treatment oflocoregionally advanced nasopharyngeal carcinoma：a retrospective controlled study
10.1186/s40880-015-0076-9
- Author:
WenZeQiu
1
;
PeiYuHuang
;
JunLiShi
;
HaiQunXia
;
ChongZhao
;
KaJiaCao
Author Information
1. Department of Nasopharyngeal Carcinoma
- Keywords:
Nasopharyngeal carcinoma;
Intensity-modulated radiotherapy;
Neoadjuvant chemotherapy;
Concurrent chemoradiotherapy;
Adjuvant chemotherapy
- From:Chinese Journal of Cancer
2016;(1):40-48
- CountryChina
- Language:Chinese
-
Abstract:
Background:In the era of intensity?modulated radiotherapy (IMRT), the role of neoadjuvant chemotherapy (NAC) for locoregionally advanced nasopharyngeal carcinoma (NPC) is under?evaluated. The aim of this study was to com?pare the effcacy of NAC plus IMRT and concurrent chemoradiotherapy (CCRT) plus adjuvant chemotherapy (AC) on locoregionally advanced NPC.
Methods:Between January 2004 and December 2008, 240 cases of locoregionally advanced NPC conifrmed by pathologic assessment in Sun Yat?sen University Cancer Center were reviewed. Of the 240 patients, 117 received NAC followed by IMRT, and 123 were treated with CCRT plus AC. The NAC+IMRT group received a regimen that included cisplatin and 5?lfuorouracil (5?FU). The CCRT+AC group received cisplatin concurrently with radiotherapy, and subsequently received adjuvant cisplatin and 5?FU. The survival rates were assessed by Kaplan–Meier analysis, and the survival curves were compared using a log?rank test. Multivariate analysis was conducted using the Cox proportional hazard regression model.
Results:The 5?year overall survival (OS), locoregional relapse?free survival (LRRFS), distant metastasis?free survival (DMFS), and disease?free survival (DFS) were 78.0, 87.9, 79.0, and 69.8%, respectively, for the NAC+IMRT group and 78.7, 84.8, 76.2, and 65.6%, respectively, for the CCRT+AC group. There were no signiifcant differences in survival between the two groups. In multivariate analysis, age (<50years vs.≥50years) and overall stage (III vs. IV) were found to be independent predictors for OS and DFS; furthermore, the overall stage was a signiifcant prognostic factor for DMFS. Compared with the CCRT+AC protocol, the NAC+IMRT protocol signiifcantly reduced the occurrence rates of grade 3–4 nausea–vomiting (6.5 vs. 1.5%,P=0.023) and leukopenia (9.7 vs. 0.8%,P=0.006).
Conclusions:The treatment outcomes of the NAC+IMRT and CCRT+AC groups were similar. Distant metastasis remained the predominant mode of treatment failure.
